Skip to main content
Top
Published in: Breast Cancer Research 2/2000

01-10-2000 | Meeting abstract

Radial scars and stellate lesions as imaging abnormalities: a comparative study

Author: A Stewart

Published in: Breast Cancer Research | Special Issue 2/2000

Login to get access

Excerpt

The aim of this study is to compare the imaging appearances of radial scars (RS), thought to be of questionable significance, to stellate lesions (SL), indicative of malignancy in up to 94% of cases (Burrell et al 1996). Mammographic appearances of RS may change depending on which projection is being viewed but may not for stellate lesions. RS are represented by an area of architectural distortion and exhibit a radiolucent core, long spicules and no calcifications. However, calcifications have been shown to be present in up to 45% of RS (Cardenosa et al 1991). SL comprise a dense core, short spicules and polymorphic calcifications. Mammographically, the two may be indeterminate. Ultrasound of both RS and SL may show similar traits: irregular outline, posterior shadowing and enhanced vascularity. Studies of contrast-enhanced MRI images show tumours to have rapid uptake with steady wash-out of gadolinium. However, this pattern can also be attributed to RS and there may be no significant enhancement differences between benign and malignant lesions (Stomper et al 1995). The specificity of MRI remains low. …
Metadata
Title
Radial scars and stellate lesions as imaging abnormalities: a comparative study
Author
A Stewart
Publication date
01-10-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr255

Other articles of this Special Issue 2/2000

Breast Cancer Research 2/2000 Go to the issue

Meeting abstract

Surgical management

Meeting abstract

Lymph node diagnosis

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine